Spotlight
Video

GRACEcastUC-005 - The TOPICAL Study: Is Rash a Predictor of Benefit with EGFR Inhibitor Therapy?

cancergrace has 795 videos Subscribe Here

Loading........
Description: http://cancerGRACE.org/...

Dr. H. Jack West reviews the TOPICAL study of Tarceva vs. placebo for marginal and poor PS patients with advanced NSCLC, which showed a clearly superior outcome with Tarceva in patients who developed a rash vs. those who don't.
Shared By : cancergrace
Posted on : 05/01/13
Added : 4 years ago
Category : General